互联网医院应遵守"处方应由接诊医师本人开具，严禁使用人工智能等自动生成处方"等刚性要求。通过 强化执业医师和药师在线服务的资质认证管理，构建标准化、规范化电子处方审核体系，确保执业医 师、药师本人真正在岗、在线，实现诊疗、审方及药学服务的全流程数字化记录，便于监管溯源。 第三方平台可引入技术手段，在问诊环节使用人脸检测，确保医师与患者身份的真实性。建立和完善处 方留痕存证平台，将诊断记录、用药方案、患者反馈等数据归档上传备查。对高风险类药物进行二次人 工复核并留存审核处理资料，关联处方、医师、药师、药品批号，阻断"秒开处方"漏洞，筑牢用药安全 防线。 长期来看，还需建立医师线上诊疗专业资质和能力认证体系，将接诊时效、病历完整度等指标纳入监督 范围，构建互联网诊疗健康生态。 （文章来源：经济日报） 近期，部分平台处方药销售乱象引发关注。购药人无需出示有效处方，只需自行勾选或添加线下已确诊 疾病，补充说明使用过该药且无过敏史等不良反应，即可完成问诊开方。甚至在疾病症状明显不对症的 情况下，未经病情诊断核实，仍能开出处方。 随着互联网医疗蓬勃发展，线上购买处方药成为不少消费者的选择。相较每次找医生重开处方，线上流 ...

Core Viewpoint - The digital healthcare service platform "Health 160" has submitted its application for listing on the Hong Kong Stock Exchange for the third time, facing challenges related to profitability and business model controversies [1][4]. Group 1: Reasons for Previous Failures - The primary reasons for "Health 160's" previous failed applications include a lack of profitability and disputes over its business model [4]. - Financially, despite revenue growth, the company has been continuously losing money with a low gross margin, which does not meet the potential profitability stability requirements of the Hong Kong market [4]. - The business model, which combines "medical appointment + health mall," has been criticized for being overly reliant on third-party collaborations for hospital registrations and drug sales, leading to a weak commercial loop [4]. - Regulatory concerns regarding data security and the definition of medical responsibility have further diminished investor confidence [4]. Group 2: Financial and Business Performance - "Health 160" derives over 60% of its revenue from registration service fees and health product sales, but high costs related to technology development and user acquisition have led to increasing losses [5]. - The business model attempts to connect the entire chain from "online registration - consultation - health management - pharmaceutical e-commerce," but each segment faces intense competition from established players [5]. - Despite accumulating a large amount of medical data, the company still needs to validate its monetization paths through precise marketing and insurance collaborations [5]. Group 3: Challenges Faced - "Health 160" faces three core challenges: 1. Policy risks due to regulations like the "Internet Diagnosis and Treatment Supervision Guidelines," which limit its profit model of directing users to offline services [6]. 2. A vague profit model, with low-margin registration and consultation services and challenging health product sales, necessitating exploration of new avenues like "medical + insurance" [6]. 3. Insufficient user stickiness, as the lack of exclusive medical resources makes it vulnerable to being replaced by public hospital apps or regional platforms [6]. - The repeated failures in listing applications have exposed governance issues within the company, and prolonged losses may lead to declining investor confidence and pressure on valuation [6].